A phase I trial to evaluate the HIV-1 SF-2 recombinant p24 subunit vaccine [HIV vaccine; Chiron vaccines] administered as a novel boost in prime-boost vaccination regimens with ALVAC-HIV vCP205 [HIV vaccine vCP205; Pasteur Merieux Connaught] and HIV-1 SF-2 rgp120 in MF59 [HIV gp120 vaccine; Chiron Vaccines]
Latest Information Update: 17 Sep 2021
At a glance
- Drugs HIV vaccine vCP205 (Primary) ; HIV gp120 vaccine; HIV vaccine
- Indications HIV-1 infections
- Focus Adverse reactions
- 06 Nov 2005 New trial record.